Compare Boston Beer Company Inc (SAM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs GeneDx Holdings Corp — how do they compare? Boston Beer Company Inc trades at $170.75 (market cap $1.88B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Boston Beer Company Inc and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| SAM | WGS | |
|---|---|---|
Market Cap | $1.88B | $1.80B |
Sector | Consumer Staples | Technology |
52-Week High | $260.05 | $167.51 |
52-Week Low | $161.08 | $34.51 |
Enterprise Value | $1.75B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $170.98, down 4.37% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, though 2026 projections show potential challenges with expected revenue decline and negative margins. Recent earnings show a mix of beats and misses, with Q2 2026 results pending.
The stock presents a cautious opportunity with analyst consensus target of $204.33 suggesting 19% upside, but faces headwinds from declining volumes, competitive pressure in hard seltzer market, and negative FY26 EPS growth projections. Institutional sentiment leans neutral with 74% hold ratings, reflecting balanced risk-reward amid evolving consumer beverage preferences.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
